Clinical dilemma of lung cancer treatment with anti‑PD‑1 therapy (nivolumab) in the discovery of rheumatological problems with joint swelling – case report


MUDr. Markéta Černovská

Pneumologická klinika 1. LF UK a Thomayerovy nemocnice, Praha



Immunotherapy is the use of medicines to stimulate a person's own immune system to recognize and destroy cancer cells more effectively. Nivolumab can be used in people with certain types of advanced NSCLC whose cancer starts growing again after chemotherapy. But immunotherapy drugs can cause side effects, including rare complications that, for some patients, may be life threatening, but most side effects are mild to moderate in severity and respond to treatments such as steroids. It’s very important to report any new side as soon as possible. Although rheumatic immune-related adverse events are rarely life-threatening, patients' quality of life can be considerably restricted due to pain, stiffness and limited mobility.


Key words

immunotherapy, nivolumab, immune-related adverse events



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...